Celularity Inc. (CELU) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Celularity Inc. is a regenerative and cellular medicines company focused on aging-related diseases, operating through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company is an emerging growth company and a smaller reporting company. On February 28, 2024, the company effected a 1-for-10 reverse stock split; all share data is adjusted to reflect this.
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | Value (in thousands) |
|---|---|
| Total Net Revenues | $26,792 |
| Net Loss | $(28,501) |
| Loss Per Share (Basic & Diluted) | $(1.32) |
| Operating Cash Flow | $(7,851) |
| Cash and Cash Equivalents | $467 |
| Restricted Cash | $10,087 |
| Total Debt (Short-term) | $40,999 |
| Accumulated Deficit | $(870,292) |
Material Changes vs. Prior Period
- Revenue Growth: Total net revenues increased by 289.8% to $26.8 million from $6.9 million in the prior year period. This was driven primarily by a 1,070% increase in product sales ($22.8 million vs. $1.9 million), attributed to higher demand for the Biovance 3L biomaterial product.
- Expense Reduction: Total operating expenses decreased by 60.8% to $44.3 million from $113.2 million. This significant reduction excludes non-cash impairments recorded in 2023, including a $107.8 million IPR&D impairment and a $29.6 million goodwill impairment. Research and development expenses dropped 62.3% due to workforce reductions and the discontinuation of certain clinical trials.
- Loss Improvement: The net loss narrowed significantly to $28.5 million from $112.0 million in the prior year, largely due to the absence of the large impairment charges and software cease-use costs ($23.9 million) recorded in 2023.
- Debt Restructuring: The company repaid the Yorkville Pre-Paid Advance Agreement in full in January 2024. It entered into a new $15.0 million senior secured bridge loan with Resorts World Inc (RWI) and a Standby Equity Purchase Agreement (SEPA) with Yorkville.
Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of $870.3 million and insufficient unrestricted cash ($0.5 million) to fund operations for the next 12 months without additional capital.
- Liquidity Crisis: Approximately $44.7 million of debt is outstanding and due within one year. Substantially all debt is subject to forbearance agreements. Failure to meet terms could lead to asset seizure or liquidation.
- Nasdaq Compliance: The company received notice of non-compliance with Nasdaq listing rules due to late filing of Q1 and Q2 2024 reports. A hearing is scheduled for December 11, 2024, to determine if the company will be delisted. Delisting could materially adversely affect the company's ability to raise capital.
- Legal Proceedings:
- Palantir: Arbitration settled in June 2024 with a payment of $3.5 million and issuance of shares.
- Evolution Biologyx: Litigation ongoing to recover approximately $2.35 million in unpaid invoices.
- False Claims Act: A Civil Investigative Demand regarding Medicare/Medicaid claims for Interfyl is in preliminary stages.
- Guidance: The filing does not provide specific forward-looking financial guidance for future quarters, citing the uncertainty of securing additional capital.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure immediate financing given the $0.5 million unrestricted cash balance and $44.7 million in near-term debt obligations.
- Nasdaq Status: Monitor the outcome of the December 11, 2024, Nasdaq Hearings Panel regarding potential delisting.
- Debt Covenants: Review the terms of the forbearance agreements with RWI, C.V. Starr, and Yorkville to understand triggers for default and potential acceleration of debt.
- Revenue Sustainability: Assess the durability of the Biovance 3L sales growth and the impact of the CMS claim rejections for Interfyl on future revenue.
- Internal Controls: Note the material weaknesses in internal controls over financial reporting identified by management, which contributed to the late filing of reports.